ArticleJournal of neurosurgery2012
Neuroprotective and neurorestorative effects of thymosin β4 treatment initiated 6 hours after traumatic brain injury in rats.
Article in Journal of neurosurgery, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 70 citations in OpenAlex.
- Oral Supplementation With a Bovine Thymus Extract Reduces Neuronal Excitability in Aging Mice.FASEB bioAdvances · 2026Article
- Thymosin β4 stabilizes hypoxia induced brain microvascular endothelial cell dysfunction through S1PR1 dependent mechanisms.Scientific reports · 2025Article
- Protein to biomaterials: Unraveling the antiviral and proangiogenic activities of Ac-TβBioactive materials · 2025Article
- Clinical Management in Traumatic Brain Injury.Biomedicines · 2024Review
- Effect of thymosin β4 on lipopolysaccharide‑stimulated brain microvascular endothelial cell remodeling: A possible role in blood‑brain barrier injury.Experimental and therapeutic medicine · 2023Article
- Antioxioxidant and antiapoptotic effects of Thymosin β4 in Aβ-induced SH-SY5Y cells via the 5-HTR1A/ERK axis.PloS one · 2023Article
- Regulation of pathological blood-brain barrier for intracranial enhanced drug delivery and anti-glioblastoma therapeutics.Oncology research · 2021Review
- Review
- MicroRNA-23a-3p improves traumatic brain injury through modulating the neurological apoptosis and inflammation response in mice.Cell cycle (Georgetown, Tex.) · 2020Article
- miR-146a mediates thymosin β4 induced neurovascular remodeling of diabetic peripheral neuropathy in type-II diabetic mice.Brain research · 2019Article
- Thymosins in multiple sclerosis and its experimental models: moving from basic to clinical application.Multiple sclerosis and related disorders · 2019Review
- Thymosin Beta 4 Is Involved in the Development of Electroacupuncture Tolerance.Frontiers in cellular neuroscience · 2019Article
- The Importance of Therapeutic Time Window in the Treatment of Traumatic Brain Injury.Frontiers in neuroscience · 2019Review
- Stem cells technology: a powerful tool behind new brain treatments.Drug delivery and translational research · 2018Review
- Exploring the Mechanisms of Electroacupuncture-Induced Analgesia through RNA Sequencing of the Periaqueductal Gray.International journal of molecular sciences · 2017Article
- Treatment of traumatic brain injury in rats with N-acetyl-seryl-aspartyl-lysyl-proline.Journal of neurosurgery · 2017Article
- Pharmacological approaches to intervention in hypomyelinating and demyelinating white matter pathology.Neuropharmacology · 2016Review
- Strategies targeting endogenous neurogenic cell response to improve recovery following traumatic brain injury.Brain research · 2016Review
- The Controlled Cortical Impact Model of Experimental Brain Trauma: Overview, Research Applications, and Protocol.Methods in molecular biology (Clifton, N.J.) · 2016Review
- Thymosin beta 4 up-regulates miR-200a expression and induces differentiation and survival of rat brain progenitor cells.Journal of neurochemistry · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
objectThymosin β4 (Tβ4) is a regenerative multifunctional peptide. The aim of this study was to test the hypothesis that Tβ4 treatment initiated 6 hours postinjury reduces brain damage and improves functional recovery in rats subjected to traumatic brain injury (TBI).
methodsTraumatic brain injury was induced by controlled cortical impact over the left parietal cortex in young adult male Wistar rats. The rats were randomly divided into the following groups: 1) saline group (n = 7); 2) 6 mg/kg Tβ4 group (n = 8); and 3) 30 mg/kg Tβ4 group (n = 8). Thymosin β4 or saline was administered intraperitoneally starting at 6 hours postinjury and again at 24 and 48 hours. An additional group of 6 animals underwent surgery without TBI (sham-injury group). Sensorimotor function and spatial learning were assessed using the modified Neurological Severity Score and the Morris water maze test, respectively. Animals were euthanized 35 days after injury, and brain sections were processed to assess lesion volume, hippocampal cell loss, cell proliferation, and neurogenesis after Tβ4 treatment.
resultsCompared with saline administration, Tβ4 treatment initiated 6 hours postinjury significantly improved sensorimotor functional recovery and spatial learning, reduced cortical lesion volume and hippocampal cell loss, and enhanced cell proliferation and neurogenesis in the injured hippocampus. The high dose of Tβ4 showed better beneficial effects compared with the low-dose treatment.
conclusionsThymosin β4 treatment initiated 6 hours postinjury provides both neuroprotection and neurorestoration after TBI, indicating that Tβ4 has promising therapeutic potential in patients with TBI. These data warrant further investigation of the optimal dose and therapeutic window of Tβ4 treatment for TBI and the associated underlying mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.